**Supplemental Figures**

Supplemental Figure 1: Cumulative absolute female breast cancer risks in *ATM* and *CHEK2* protein-truncating/missense variant carriers and the general female population by age

Supplemental Figure 2: Cumulative absolute prostate cancer risks in *ATM* and *CHEK2* protein-truncating/missense variant carriers and the general male population by age

Supplemental Figure 3: Cumulative absolute any cancer (other than non melanoma skin cancer) risks for female *ATM* and *CHEK2* protein-truncating/missense variant carriers and the general female population by age

Supplemental Figure 4: Cumulative absolute any cancer (other than non melanoma skin cancer) risks for male *ATM* and *CHEK2* protein-truncating/missense variant carriers and the general male population by age

1For breast cancer in *ATM* truncating variant carriers, where there was evidence of a decline of risk with age, HRs from the time-dependent model in Supplemental Table 1 were used. In all other cases a constant HR was assumed.

1For any cancer in females in *ATM* truncating variant carriers, where there was evidence of a decline of risk with age, HRs from the time-dependent model in Supplemental Table 1 were used. In all other cases a constant HR was assumed.